Merck triggers a new round of layoffs in R&D reorganization, pushing more jobs into Cambridge, San Francisco
Merck is confirming that it’s triggered a new round of layoffs in its R&D group as it concentrates and expands its drug research work in two major biotech hubs, Cambridge, MA and San Francisco. The restructuring includes adding a new lab in Cambridge, which will focus on the fast-growing microbiome field.
A spokesperson for Merck tells me:
“Within Merck Research Laboratories, we are making some organizational changes within our discovery, pre-clinical and early development area to enable earlier access to emerging external science and technology to augment our leading discovery and development capabilities. These changes include increasing our investment in exploratory biology in areas where biomedical research is converging, specifically in Cambridge, Mass. and the San Francisco Bay area, Calif. Unfortunately, these changes will result in workforce reductions at our Kenilworth and Rahway, N.J. sites and our North Wales, Pa. screening facility as we shift resources and personnel.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.